Skip to main content

Advertisement

Table 1 Demographic and Cancer Treatment-Related Characteristics (N = 220)

From: Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy

Variable Intervention (N = 108) Control (N = 112) p value
Age at Baseline    p = 0.33
 Median (Range) 54 (26–86) 56 (22–87)  
Time on Study (Days)    p = 0.64
 Median (Range) 122 (49–482) 113 (49–378)  
Gender    p = 0.89
 Male 51 (47%) 51 (46%)  
 Female 57 (53%) 61 (54%)  
Ethnicity/Race    p = 0.95
 Caucasian 94 (87%) 98 (87%)  
 Minority 4 (4%) 3 (3%)  
 Missing 10 (9%) 11 (10%)  
Working Status    p = 0.49
 Working 72 (67%) 79 (71%)  
 Not working 29 (27%) 23 (20%)  
 Missing 7 (6%) 10 (9%)  
Clinical Service    p = 0.83
 Medical Oncology 95 (88%) 100 (89%)  
 Radiation Oncology 13 (12%) 12 (11%)  
Cancer Diagnosisa    p = 0.83
 Breast 34 (31%) 42 (38%)  
 Head and Neck 17 (16%) 14 (12%)  
 Colorectal 16 (15%) 14 (12%)  
 Prostate 12 (11%) 10 (9%)  
 Esophageal 7 (6%) 3 (3%)  
 Testicular 7 (6%) 5 (4%)  
 Gastrointestinal Other 4 (4%) 2 (2%)  
 Other 4 (4%) 3 (3%)  
 Sarcoma 3 (3%) 0  
 Bladder 2 (2%) 9 (8%)  
 Gastric 2 (2%) 5 (4%)  
 Pancreatic 0 1 (1%)  
 Unknown Primary 0 4 (4%)  
Stage    p = 0.29
 I 14 (13%) 19 (16%)  
 II 30 (28%) 29 (26%)  
 III 30 (28%) 22 (20%)  
 IV 30 (28%) 40 (36%)  
 Missing 4 (4%) 2 (2%)  
Chemotherapy Type    p = 0.98
 Taxane Only 62 (58%) 62 (55%)  
 Platinum Only 39 (36%) 42 (38%)  
 Platinum and Taxane 7 (6%) 8 (7%)  
Cumulative Dose Categoryb    p = 0.31
 Low Dosec 25 (23%) 26 (23%)  
 Moderate Dosed 35 (32%) 48 (43%)  
 High Dosee 47 (44%) 37 (33%)  
 Missing 1 (1%) 1 (%)  
Neurotoxic Chemotherapy Dose Reduction    p = 0.60
 None 96 (89%) 104 (93%)  
 Neuropathy-Related 9 (8%) 6 (5%)  
 Other Symptom-Relatedf 3 (3%) 2 (2%)  
  1. This table describes the demographic characteristics of the patients at baseline
  2. aTo compare distribution of cancer diagnosis for intervention versus control, the diagnoses with < 10 observations are grouped together into another category (i.e., esophageal, testicular, gastrointestinal, miscellaneous, sarcoma, bladder, gastric, pancreatic and unknown primary)
  3. bFor participants receiving multiple neurotoxic chemotherapy agents, dose category was determined based on the highest dose of one of the specific agents they were receiving
  4. cPaclitaxel < 700 mg/m2; Oxaliplatin < 800 mg/m2; Docetaxel < 300 mg/m2; Cisplatin < 300 mg/m2
  5. dPaclitaxel 700–1400 mg/m2; Oxaliplatin 800–1000 mg/m2; Docetaxel 300–600 mg/m2; Cisplatin 300–600 mg/m2
  6. ePaclitaxel > 1400 mg/m2; Oxaliplatin > 1000 mg/m2; Docetaxel > 600 mg/m2; Cisplatin > 600 mg/m2
  7. fNeurotoxic chemotherapy dose reduction due to other symptom-related causes included fatigue, pain, skin changes, bowel problems, or breathing problems